Skip to content
ePORE Therapy Logo
  • About Mirai
  • Technology
    • What is Electroporation?
    • ePORE® therapy Technology
    • ePORE® therapy Treats
    • Benefits of ePORE® therapy
    • EndoVE®
    • CUTIS
  • Skin Therapy
    • Clinicians
    • Patient Information
  • Gastrointestinal Therapy
    • Clinicians
    • Patient Information
  • News
  • References
  • Contact
Menu
  • About Mirai
  • Technology
    • What is Electroporation?
    • ePORE® therapy Technology
    • ePORE® therapy Treats
    • Benefits of ePORE® therapy
    • EndoVE®
    • CUTIS
  • Skin Therapy
    • Clinicians
    • Patient Information
  • Gastrointestinal Therapy
    • Clinicians
    • Patient Information
  • News
  • References
  • Contact

Category: News

Filter by Topic
Mirai Medical Launches its New Website and has Received a Favourable Ethical Opinion for the PIONEER Patient Registry
Read More
24.05.2021
First Patient Enrolled in VECTOR Trial using ePORE® therapy for the Treatment of Inoperable Oesophageal and Gastric Cancer
Read More
10.05.2021
Galway-based Mirai Medical raises €3m in funding
Read More
25.03.2021

Contact Us

By clicking send, you confirm you have read and agreed to Mirai Medical's Privacy Policy.
Twitter Linkedin-in Youtube
ePORE Therapy White Logo
Address:
Mirai Medical
Unit 5, Howley Court
Oranmore
Galway
Ireland
Email:
info@mirai-medical.com
Mirai Medical logo white
Dynamic Meta widget allowed only for Posts listing source or in Post context
Privacy & Cookies
ePORE® therapy, EndoVE® and CUTIS are approved for commercialisation in the European Union, United Kingdom and Australia. ePORE® therapy, EndoVE® and CUTIS are not cleared by FDA for commercialisation in the USA.
Website by Proactive Design & Marketing